Identifying molecular signatures in allergic contact dermatitis
Molecular Diagnosis of Allergic Contact Dermatitis
This study is trying to see if looking at the molecular details of skin samples from adults with allergic contact dermatitis can help doctors diagnose the condition more quickly and easily.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT06177314 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the diagnosis of allergic contact dermatitis (ACD) by correlating molecular signatures from active skin lesions with results from traditional allergological testing. It focuses on patients over 18 years old who have active dermatitis lesions and have undergone patch testing. The study seeks to streamline the diagnostic process, which is currently lengthy and requires specialized expertise. By analyzing the molecular profiles of skin biopsies, the research hopes to enhance understanding and identification of ACD.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with active contact dermatitis lesions who have previously undergone patch testing.
Not a fit: Patients without active dermatitis lesions or those who have not undergone patch testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to faster and more accurate diagnoses of allergic contact dermatitis, improving patient outcomes.
How similar studies have performed: While the approach of correlating molecular signatures with clinical outcomes is promising, it is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, male or female, over 18 years of age * Patient with active contact dermatitis lesion biopsied for molecular analysis * Patients who have undergone patch testing * Patients whose positive patch tests were biopsied for molecular analysis * Written informed consent given prior to any study-related procedure * Between 01/01/2020 and 31/12/2025 Exclusion Criteria: * Missing clinical data * Patient objecting to use of data
Where this trial is running
Pierre-Bénite
- Centre Hospitalier Lyon Sud — Pierre-Bénite, France (Recruiting)
Study contacts
- Study coordinator: Audrey NOSBAUM, MD, PhD
- Email: Audrey.nosbaum@chu-lyon.fr
- Phone: 04 78 86 12 85
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.